Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer



Status:Recruiting
Conditions:Breast Cancer, High Blood Pressure (Hypertension)
Therapuetic Areas:Cardiology / Vascular Diseases, Oncology
Healthy:No
Age Range:Any
Updated:3/16/2019
Start Date:March 25, 2014
End Date:January 1, 2100

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples

This research trial studies whole exome sequencing in finding causative variants in germline
deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for
breast cancer. Studying samples of germline DNA in the laboratory from patients with
hypertension receiving bevacizumab for breast cancer may help doctors learn about changes
that occur in DNA and identify biomarkers related to hypertension.

PRIMARY OBJECTIVES:

I. To identify, using next generation sequencing, rare variants of large effect size that
impact the risk of hypertension in patients from the clinical trial Eastern Cooperative
Oncology Group (ECOG)-5103 (E5103).

OUTLINE:

Previously collected germline DNA samples are analyzed via whole exome sequencing.

Inclusion Criteria:

- European American patients with deoxyribonucleic acid (DNA) available and designated
case or control

- Patients who developed grade 3-4 bevacizumab-induced hypertension during their
treatment with bevacizumab

- Patients who did not develop hypertension following a full course of treatment with
bevacizumab
We found this trial at
1
site
Eastern Cooperative Oncology Group
Boston, Massachusetts 02215
Principal Investigator: Bryan P. Schneider
Phone: 317-274-6473
?
mi
from
Boston, MA
Click here to add this to my saved trials